阿尔茨海默病的生物标志物：指明道路还是误导我们？
Biomarkers for Alzheimer's disease: showing the way or leading us astray?
机构信息
Oregon Health and Science University and Portland VA Medical Center, Portland, OR 97239, USA.
出版信息
J Alzheimers Dis. 2013;33 Suppl 1(Suppl 1):S371-6. doi: 10.3233/JAD-2012-129022.
Abstract
The indolent nature of Alzheimer's disease, coupled with burgeoning interest in a "presymptomatic" stage of disease, has motivated efforts to identify, validate, and exploit surrogate disease markers for trials of disease-modifying or preventive strategies. Many of these efforts have been productive, and biomarkers are now routinely applied in selection of study subjects and evaluation of outcomes in clinical trials. On the other hand, biomarkers also have the capacity to lead to bad therapeutic outcomes when they determine "go- no go" decisions in early drug development. This paper reviews several reports of biomarker studies which illustrate the great potential, for both good and ill, of biomarkers of Alzheimer's disease.
摘要
阿尔茨海默病的惰性特征，加上人们对疾病“前临床阶段”日益增长的兴趣，促使人们努力识别、验证和利用替代疾病标志物，以进行疾病修饰或预防策略的试验。这些努力中有许多是富有成效的，生物标志物现在已被常规用于研究对象的选择和临床试验结果的评估。另一方面，生物标志物也有可能在早期药物开发中决定“前进或停止”决策时导致不良的治疗结果。本文综述了几项生物标志物研究报告，这些报告说明了阿尔茨海默病生物标志物具有巨大的潜力，既有好的方面，也有坏的方面。
相似文献
1
Biomarkers for Alzheimer's disease: showing the way or leading us astray?阿尔茨海默病的生物标志物：指明道路还是误导我们？
J Alzheimers Dis. 2013;33 Suppl 1(Suppl 1):S371-6. doi: 10.3233/JAD-2012-129022.
2
Prevention Trials in Alzheimer's Disease: Current Status and Future Perspectives.阿尔茨海默病的预防试验：现状与未来展望
J Alzheimers Dis. 2016;50(4):927-45. doi: 10.3233/JAD-150826.
3
Biomarkers in Alzheimer's disease drug development.阿尔茨海默病药物研发中的生物标志物。
Alzheimers Dement. 2011 May;7(3):e13-44. doi: 10.1016/j.jalz.2010.06.004. Epub 2011 May 6.
4
Lost in Translation? Finding Our Way To Effective Alzheimer's Disease Therapies.迷失在翻译中？寻找有效的阿尔茨海默病疗法。
J Alzheimers Dis. 2018;64(s1):S33-S39. doi: 10.3233/JAD-179930.
5
The biomarker and therapeutic potential of miRNA in Alzheimer's disease.微小RNA在阿尔茨海默病中的生物标志物及治疗潜力
Neurodegener Dis Manag. 2015;5(1):61-74. doi: 10.2217/nmt.14.52.
6
A review of biomarkers of Alzheimer's disease in noninvasive samples.非侵入性样本中阿尔茨海默病生物标志物的综述。
Biomark Med. 2018 Jun;12(6):677-690. doi: 10.2217/bmm-2017-0388. Epub 2018 Jun 13.
7
Lipid Biomarkers in Alzheimer's Disease.阿尔茨海默病中的脂质生物标志物
Curr Alzheimer Res. 2018 Feb 22;15(4):303-312. doi: 10.2174/1567205014666170505101426.
8
Biomarkers in Sporadic and Familial Alzheimer's Disease.散发性和家族性阿尔茨海默病中的生物标志物
J Alzheimers Dis. 2015;47(2):291-317. doi: 10.3233/JAD-143006.
9
Biomarkers in Alzheimer's disease drug development.阿尔茨海默病药物研发中的生物标志物。
Nat Med. 2010 Nov;16(11):1218-22. doi: 10.1038/nm.2221. Epub 2010 Sep 21.
10
Biomarkers for preclinical Alzheimer's disease.临床前阿尔茨海默病的生物标志物。
J Alzheimers Dis. 2014;42(4):1051-69. doi: 10.3233/JAD-140843.
引用本文的文献
1
Performance of Validated MicroRNA Biomarkers for Alzheimer's Disease in Mild Cognitive Impairment.阿尔茨海默病轻度认知障碍中经过验证的 microRNA 生物标志物的性能。
J Alzheimers Dis. 2020;78(1):245-263. doi: 10.3233/JAD-200396.
2
Comparison of Noninvasive Imagery Methods to Observe Healthy and Degenerated Olfactory Epithelium in Mice for the Early Diagnosis of Neurodegenerative Diseases.用于神经退行性疾病早期诊断的小鼠健康和退化嗅上皮观察的非侵入性成像方法比较
Front Neuroanat. 2020 Jul 14;14:34. doi: 10.3389/fnana.2020.00034. eCollection 2020.
3
Validation of MicroRNA Biomarkers for Alzheimer's Disease in Human Cerebrospinal Fluid.阿尔茨海默病患者脑脊液中 microRNA 生物标志物的验证。
J Alzheimers Dis. 2019;67(3):875-891. doi: 10.3233/JAD-180539.
4
MicroRNAs in Human Cerebrospinal Fluid as Biomarkers for Alzheimer's Disease.人脑脊液中的微小RNA作为阿尔茨海默病的生物标志物
J Alzheimers Dis. 2017;55(3):1223-1233. doi: 10.3233/JAD-160835.
5
Global protein differential expression profiling of cerebrospinal fluid samples pooled from Chinese sporadic CJD and non-CJD patients.对来自中国散发性克雅氏病患者和非克雅氏病患者的脑脊液样本进行的全球蛋白质差异表达谱分析。
Mol Neurobiol. 2014 Feb;49(1):290-302. doi: 10.1007/s12035-013-8519-2. Epub 2013 Aug 4.
本文引用的文献
1
What the halted phase III γ-secretase inhibitor trial may (or may not) be telling us.三期γ-分泌酶抑制剂试验的中止可能（或可能不）告诉了我们什么。
Ann Neurol. 2011 Feb;69(2):237-9. doi: 10.1002/ana.22365.
2
Docosahexaenoic acid supplementation and cognitive decline in Alzheimer disease: a randomized trial.二十二碳六烯酸补充剂与阿尔茨海默病认知能力下降：一项随机试验。
JAMA. 2010 Nov 3;304(17):1903-11. doi: 10.1001/jama.2010.1510.
3
Rosiglitazone monotherapy in mild-to-moderate Alzheimer's disease: results from a randomized, double-blind, placebo-controlled phase III study.罗格列酮单药治疗轻中度阿尔茨海默病的随机、双盲、安慰剂对照 III 期研究结果。
Dement Geriatr Cogn Disord. 2010;30(2):131-46. doi: 10.1159/000318845. Epub 2010 Aug 21.
4
Uric acid as a CNS antioxidant.尿酸作为中枢神经系统的抗氧化剂。
J Alzheimers Dis. 2010;19(4):1331-6. doi: 10.3233/JAD-2010-1330.
5
Effect of tarenflurbil on cognitive decline and activities of daily living in patients with mild Alzheimer disease: a randomized controlled trial.他克林对轻中度阿尔茨海默病患者认知功能下降及日常生活活动能力的影响：一项随机对照试验。
JAMA. 2009 Dec 16;302(23):2557-64. doi: 10.1001/jama.2009.1866.
6
Ascorbic acid and rates of cognitive decline in Alzheimer's disease.抗坏血酸与阿尔茨海默病的认知衰退速率
J Alzheimers Dis. 2009;16(1):93-8. doi: 10.3233/JAD-2009-0923.
7
Phase 2 safety trial targeting amyloid beta production with a gamma-secretase inhibitor in Alzheimer disease.在阿尔茨海默病中使用γ-分泌酶抑制剂针对β淀粉样蛋白生成的2期安全性试验。
Arch Neurol. 2008 Aug;65(8):1031-8. doi: 10.1001/archneur.65.8.1031.
8
CSF multianalyte profile distinguishes Alzheimer and Parkinson diseases.脑脊液多分析物谱可区分阿尔茨海默病和帕金森病。
Am J Clin Pathol. 2008 Apr;129(4):526-9. doi: 10.1309/W01Y0B808EMEH12L.
9
Classification and prediction of clinical Alzheimer's diagnosis based on plasma signaling proteins.基于血浆信号蛋白的临床阿尔茨海默病诊断分类与预测
Nat Med. 2007 Nov;13(11):1359-62. doi: 10.1038/nm1653. Epub 2007 Oct 14.
10
CSF tau/Abeta42 ratio for increased risk of mild cognitive impairment: a follow-up study.脑脊液tau蛋白与β淀粉样蛋白42比值升高提示轻度认知障碍风险增加：一项随访研究。
Neurology. 2007 Aug 14;69(7):631-9. doi: 10.1212/01.wnl.0000267428.62582.aa.
Zotero 插件